MEDIASTINAL WIDENING WITH ISOLATED BULBAR WEAKNESS- A MASQUERADE OF MYASTHENIA GRAVIS.
Abstract
approximately 0.15 per lakh population per year. Thymoma is
usually a begin tumour from anterior mediastinum. About one
third of cases were diagnosed during Myasthenia Gravis
evaluation. One third as asymptomatic mass, one third as
obstructive features. Myasthenia Gravis is the common
para-neoplastic syndrome associated with Thymoma. Ocular
weakness is most typical and usual presentation with or
without limb involvement, while early or isolated oropharngeal
or limb weakness is very rare. Mainstay of treatment of
Thymoma with Myasthenia Gravis is surgical resection with
adequate preoperative preparations such as plasmapheresis
or IV Immunoglobulin.
Full Text:
PDFReferences
amil Nadu Dr. M.G.R. Medical University
University Journal of Medicine and Medical Specialities
in the clinical diagnosis, as well as arranging for appropriate
pharmacological, electrophysiological, serological and imaging
studies which obivates the delay in diagnosis of thymoma, having
good prognosis on early diagnosis.
REFERANCES:
Engels EA. Epidemiology of thymoma and associated
malignancies. J Thorac Oncol 2010;5:S260-5
Inoue M1, Kojima Y, Kinboshi M, Nakagawa T, Kanda M,
Shibasaki H., A case of myasthenia gravis presenting solely with
bulbar palsy unassociated with easy fatigability, Rinsho
Shinkeigaku. 2013;53(3):229-34.
Detterbeck FC, Parsons AM. Management of stage I and II
thymoma. Thorac Surg Clin 2011;21:59-67.
Venuta F, Rendina EA, Longo F, et al. Long-term outcome after
multimodality treatment for stage III thymic tumors. Ann Thorac
Surg 2003;76:1866-72.
STAGE TREATMENT
IComplete surgical excision
IIComplete surgical excision and postoperative radiotherapy to
decrease the incidence of local recurrence
IIIComplete surgical excision and postoperative radiotherapy to
decrease the incidence of local recurrence
IV Surgical debulking, radiotherapy, and chemotherapy 5. Lewis JE,
Wick MR, Scheithauer BW, et al. Thymoma. A clinicopathologic
review. Cancer 1987;60:2727-43.
Detterbeck FC, Moran C, Huang J, et al. Which way is up?
Policies and procedures for surgeons and pathologists regarding
resection specimens of thymic malignancy. J Thorac Oncol
;6:S1730-8.
Marom EM. Imaging thymoma. J Thorac Oncol 2010;5:S296-303.
Yamakawa Y, Masaoka A, Hashimoto T, et al. A tentative
tumor-node-metastasis classification of thymoma. Cancer
;68:1984-7.
Pescarmona E, Rendina EA, Venuta F, et al. The prognostic
implication of thymoma histologic subtyping. A study of 80
consecutive cases. Am J Clin Pathol 1990;93:190-5.
Nakagawa K, Asamura H, Matsuno Y, et al. Thymoma: a
clinicopathologic study based on the new World Health Organization
classification. J Thorac Cardiovasc Surg 2003;126:1134-40.
Okumura M, Ohta M, Tateyama H, et al. The World Health
Organization histologic classification system reflects the oncologic
behavior of thymoma: a clinical study of 273 patients. Cancer
;94:624-32.
Okumura M, Shiono H, Inoue M, et al. Outcome of surgical
treatment for recurrent thymic epithelial tumors with reference to
world health organization histologic classification system. J Surg
Oncol 2007;95:40-4.
Utsumi T, Shiono H, Kadota Y, et al. Postoperative radiation
therapy after complete resection of thymoma has little impact on
survival. Cancer 2009;115:5413-20.
Kondo K. Optimal therapy for thymoma. J Med Invest
;55:17-28.
Korst RJ, Kansler AL, Christos PJ, et al. Adjuvant radiotherapy
for thymic epithelial tumors: a systematic review and meta-analysis.
Ann Thorac Surg 2009;87:1641-7.
Venuta F, Anile M, Rendina EA, et al. The value of
transcapsular invasion in patients with thymoma. Arch Pathol Lab
Med 2009;133:1364-5.
Maggi G, Casadio C, Ardissone F, et al. Thymoma: results of
operated cases. Acta Otorhinolaryngol Ital 1990; 10:109.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
An initiative of The Tamil Nadu Dr M.G.R. Medical University